A study has revealed that blocking a molecule called IRE1α could prevent the release of neutrophil extracellular traps in lupus pathogenesis.
List view / Grid view
Filter the results
According to new research, the bioactive compound of ginger root, 6-gingerol, prevented disease progression of lupus in mice.
A new study shows how the Bcl6 protein can regulate T follicular helper cells, presenting a target for autoimmune and infectious diseases.
Researchers observed that deleting the IRE1-alpha gene caused beta cells to de-differentiate and then re-differentiate in mice, preventing immune system auto-activation.
Scientists have found that a molecule present in our blood, called C4BP (β-), could be used in a therapeutic capacity for lupus as well as potentially other autoimmune disorders.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
A new study may lead to new treatments for lupus as it has found that, when impaired, a key regulator of the immune system can cause damaging immune system attacks on skin and organs, which are hallmarks of the disease.
A new discovery on how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus.
New research findings suggest that gut microbiota may regulate lupus flares in pregnant women, presenting a therapeutic target.
Researchers have discovered that the activation of brain cells contributes to the memory loss and other cognitive impairments suffered by many patients with systemic lupus erythematosus...
Researchers have developed an index that identifies the risk for lupus based on the presence and amount of IgG and IgM antibodies and levels of C1q...
Researchers at the Medical University of South Carolina (MUSC) have identified a novel checkpoint of peripheral tolerance, specifically in B cells.
A research team has discovered the process - and filmed the actual moment - that can change the body’s response to a dying cell.
Massachusetts General Hospital (MGH) investigators use enzyme treatment to convert autoantibodies into anti-inflammatory antibodies in animal models of two autoimmune diseases.